This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Dr. Xiao et al. investigated the association of nonalcoholic fatty liver disease (NAFLD) and fibrosis with incident dementia and cognition among participants in the Rotterdam Study, a prospective cohort study that included 3,975 patients with available fatty liver index (FLI), 4,577 patients with abdominal ultrasound, and 3,300 patients with liver stiffness assessments. NAFLD was defined as FLI ≥60 or steatosis on ultrasound and fibrosis as liver stiffness ≥8.0 kPa. Over 5 or more years of follow-up, NAFLD and liver fibrosis were not associated with an increased risk of incident dementia, and NAFLD was not associated with impaired cognitive function. Of interesting, NAFLD diagnosis was associated with a significantly decreased risk of incident dementia in the first 5 years of follow-up after FLI assessment. In response, Dr. Gupta notes the current lack of a biological model for linking NAFLD to protection from dementia, seeks evidence for weight loss–induced NAFLD regression, and wonders what phenomena might be occurring in these patients before vs after 5 years of follow-up to explain the study observations. Responding to these comments, the authors note that weight loss is the hallmark of NAFLD regressions, citing studies where regressions occurred even with slight weight reductions. They also note the interesting observation in several dementia cohorts (including theirs) of weight loss occurring in the years before dementia onset. By excluding the initial years of follow-up to address confounding by these intertwined mechanisms of weight loss and dementia, they note that the apparent beneficial effect of NAFLD disappeared. They posit that the presence of NAFLD may simply reflect the absence of weight loss rather than any true protective effect against dementia, but note the need for further studies to clarify these questions. This correspondence highlights the challenges of disentangling the complex interplay between weight loss and the natural history of NAFLD and dementia.
Dr. Xiao et al. investigated the association of nonalcoholic fatty liver disease (NAFLD) and fibrosis with incident dementia and cognition among participants in the Rotterdam Study, a prospective cohort study that included 3,975 patients with available fatty liver index (FLI), 4,577 patients with abdominal ultrasound, and 3,300 patients with liver stiffness assessments. NAFLD was defined as FLI ≥60 or steatosis on ultrasound and fibrosis as liver stiffness ≥8.0 kPa. Over 5 or more years of follow-up, NAFLD and liver fibrosis were not associated with an increased risk of incident dementia, and NAFLD was not associated with impaired cognitive function. Of interesting, NAFLD diagnosis was associated with a significantly decreased risk of incident dementia in the first 5 years of follow-up after FLI assessment. In response, Dr. Gupta notes the current lack of a biological model for linking NAFLD to protection from dementia, seeks evidence for weight loss–induced NAFLD regression, and wonders what phenomena might be occurring in these patients before vs after 5 years of follow-up to explain the study observations. Responding to these comments, the authors note that weight loss is the hallmark of NAFLD regressions, citing studies where regressions occurred even with slight weight reductions. They also note the interesting observation in several dementia cohorts (including theirs) of weight loss occurring in the years before dementia onset. By excluding the initial years of follow-up to address confounding by these intertwined mechanisms of weight loss and dementia, they note that the apparent beneficial effect of NAFLD disappeared. They posit that the presence of NAFLD may simply reflect the absence of weight loss rather than any true protective effect against dementia, but note the need for further studies to clarify these questions. This correspondence highlights the challenges of disentangling the complex interplay between weight loss and the natural history of NAFLD and dementia.
Footnotes
Author disclosures are available upon request (journal{at}neurology.org).
- © 2023 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
